Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Shares Slide 5.5 Percent on Faint Q4

NEW YORK (GenomeWeb News) — Shares in Compugen slid 5.53 percent, or $.16, to $2.83 in mid-afternoon trading today after the company reported a 20-percent jump in R&D spending and a 12-percent jump in net loss atop weak revenue.
 
As GenomeWeb News reported this morning, Compugen also said it may need to raise additional cash by the middle of 2009 if it continues spending as it has been.
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.